NCT03766958已完成不适用
An Observational Registry Study to Evaluate the Performance of the BDX-XL2 Test
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 842
- 试验地点
- 15
- 主要终点
- Statistically significant change in the proportion of benign lung nodules managed by Nodify Lung experiencing invasive procedures.
研究概览
简要总结
The purpose of the ORACLE Registry is to demonstrate clinical utility of the BDX-XL2 test; specifically, the potential to reduce unnecessary invasive procedures, such as biopsies and surgeries, on benign lung nodules while not significantly increasing the number of malignant lung nodules routed to CT surveillance. Clinical data will be collected from participating patients to evaluate the impact of the BDX-XL2 test when used in the clinical management of recently identified lung nodules assessed to have a low to moderate risk of cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has provided informed consent to participate in the registry and agrees to comply with all protocol requirements.
- •Patient meets the criteria for the intended use population of Nodify Lung testing:
- •Patient is > 40 years of age at the time of the discovery of the lung nodule of concern.
- •The maximal dimension of the patient's lung nodule of concern is > 8mm and < 30mm.
- •The pre-test risk of cancer as determined by the Mayo risk prediction algorithm is 65% or less.
- •The first CT scan identifying the lung nodule of concern was performed within 60 days of patient enrollment in the registry.
排除标准
- •Nodule work-up before the time of patient enrollment indicating any attempted or completed biopsy procedure after the first CT scan identifying the lung nodule of concern.
- •High risk per physician assessment (i.e. > 65% by physician pCA)
- •Current diagnosis of any active cancer.
- •Prior diagnosis of lung cancer.
- •Prior diagnosis of any cancer within 5 years of lung nodule detection, except for non-melanomatous skin cancer.
- •Concurrent participation in any unrelated clinical trial that may impact or alter the management of the patient's nodule of concern.
- •Any illness or factor that will prevent compliance with follow-up as recommended.
结局指标
主要结局
Statistically significant change in the proportion of benign lung nodules managed by Nodify Lung experiencing invasive procedures.
时间窗: Up to 2 years
次要结局
未报告次要终点
研究者
研究点 (15)
Loading locations...
相似试验
终止
不适用
Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCDSickle Cell DiseaseNCT04930445Pfizer265
已完成
不适用
DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to DiureticsAcute Decompensated Heart FailureNCT04877652Revamp Medical Ltd.6
已完成
不适用
Product Surveillance Registry- Deep Brain Stimulation for EpilepsyRefractory EpilepsyNCT01521754MedtronicNeuro191
Unknown
不适用
A Clinical Registry to Track the Real World Use of the Saber-C® Cervical Fusion DeviceCervical Disc DiseaseNCT06240221Research Source200
已完成
不适用
An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast CancerBreast CancerNCT01725386Hoffmann-La Roche274